Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Tumor-Infiltrating Immune Cells Are More Abundant in Lung Metastases From Colorectal Cancer Than in Paired Primary Tumors and Their Prognostic Value Depends on Adjuvant Chemotherapy.

Cancer medicine·2026

Same author

COMP-PMEPA1 axis promotes epithelial-to-mesenchymal transition in breast cancer cells.

Molecular oncology·2026

Same author

Tumour acidosis remodels the glycocalyx to control lipid scavenging and ferroptosis.

Nature cell biology·2026

Same author

Screening for Peptides to Bind and Functionally Inhibit SARS-CoV-2 Fusion Peptide Using Mirrored Combinatorial Phage Display and Human Proteomic Phage Display.

Molecules (Basel, Switzerland)·2026

Same author

Complement activation in anti-glomerular basement membrane disease before and after treatment with imlifidase.

Clinical kidney journal·2026

Same author

Intracellular C3 regulates the immune response to infection via NF-κB signaling.

Cellular and molecular life sciences : CMLS·2025

Search research articles

Related Experiment Video

Updated: Jun 11, 2025

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment.

Karolina I Smolag¹, Jakub Olszowka¹, Rebecca Rosberg²

¹Section of Medical Protein Chemistry, Department of Translational Medicine, Lund University, Malmö, Sweden.

Cancer Immunology Research

|October 8, 2024

Summary

This summary is machine-generated.

Complement factor H (FH) promotes regulatory T cell (Treg) survival and function in glioma, contributing to an immunosuppressive tumor microenvironment and worse patient prognosis. Evaluating FH may predict immunotherapy response.

More Related Videos

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Related Experiment Videos

Last Updated: Jun 11, 2025

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Area of Science:

Neuro-oncology
Immunology
Molecular Biology

Background:

Glioma survival rates remain poor despite advances in immunotherapy, partly due to an immunosuppressive tumor microenvironment.
Regulatory T cells (Tregs) are key mediators of immune tolerance within the glioma microenvironment.

Purpose of the Study:

To investigate the role of complement factor H (FH) in regulating Tregs within the glioma microenvironment.
To determine the impact of FH on Treg function, glioma progression, and patient prognosis.

Main Methods:

Investigated FH as an ICOS ligand and its effect on Treg survival, function, and cytokine secretion (TGFβ, IL10).
Assessed FH production by glioma cells in human and mouse samples.
Analyzed FH expression in relation to Treg presence and patient prognosis using database investigations.
Utilized a mouse glioma model to evaluate the in vivo effect of FH knockdown on Tregs and survival.

Main Results:

FH was identified as an ICOS ligand that enhances Treg survival and function, promoting immunosuppression.
FH induces secretion of TGFβ and IL10 by Tregs, suppressing T-cell proliferation.
Glioma cells were found to directly produce FH.
Upregulated FH expression correlated with increased Treg presence and poorer glioma patient prognosis.
FH knockdown in a mouse model reduced ICOS+ Tregs and showed a trend towards prolonged survival.

Conclusions:

FH plays a critical role in fostering an immunosuppressive glioma microenvironment by promoting Treg accumulation and function.
FH is a potential biomarker for predicting glioma prognosis and response to immunotherapy.
Targeting FH or Tregs could represent a novel therapeutic strategy for glioma.